An integrated bioinformatical analysis to evaluate the role of KIF4A as a prognostic biomarker for breast cancer
Authors Xue D, Cheng P, Han M, Liu X, Xue L, Ye C, Wang K, Huang J
Received 6 February 2018
Accepted for publication 28 April 2018
Published 10 August 2018 Volume 2018:11 Pages 4755—4768
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 2
Editor who approved publication: Dr William Cho
Dan Xue,1,* Pu Cheng,2,* Mengjiao Han,3 Xiyong Liu,4,5 Lijun Xue,6 Chenyi Ye,7 Ke Wang,8 Jian Huang8,9
1Department of Plastic Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; 2Department of Gynaecology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China; 3Department of Medical Oncology, Key Laboratory of Biotherapy in Zhejiang, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China; 4Biomarker Development, California Cancer Institute, Temple City, CA, USA; 5School of Medicine, Taipei Medical University, Taipei, Taiwan, Republic of China; 6Department of Pathology, Loma Linda University Medical Center, Loma Linda, CA, USA; 7Department of Orthopaedics, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; 8Department of Surgical Oncology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China; 9Gastroenterology Institute, Zhejiang University School of Medicine, Hangzhou, China
*These authors contributed equally to this work
Purpose: The aim of this study was to investigate the diagnostic and prognostic value of human kinesin family member 4A (KIF4A) as an effective biomarker for breast cancer.
Materials and methods: Cancer Genome Atlas data and 12 independent public breast cancer microarray data sets were downloaded and analyzed using individual and pooled approaches.
Results: The results of our study revealed a strong and positive correlation between KIF4A expression and malignant features of breast cancer. KIF4A had a strong prognostic value in both ER-positive and ER-negative breast cancers comparable to or even better than tumor size, lymph node invasion, and Elston grade. We also found that KIF4A might be the target gene of microRNA-335, which can suppress KIF4A expression by targeting the 3′-untranslated region of its mRNA.
Conclusion: KIF4A might serve as a robust prognostic predictor for breast cancer. Targeting KIF4A activity could be a promising therapeutic option in breast cancer treatment.
Keywords: breast cancer, KIF4A, microarray, microRNA, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]